Letter: TIPSS is a promising therapy for sarcopenia in cirrhosis

Penelope Hey^{1

2}, Marie Sinclair^{1

2}, Adam Testro^{1

2}, Paul Gow^{1

2}

Affiliations

Comment

Penelope Hey et al. Aliment Pharmacol Ther. 2021 Jan.

. 2021 Jan;53(1):209.

doi: 10.1111/apt.16128.

Penelope Hey^{1

2}, Marie Sinclair^{1

2}, Adam Testro^{1

2}, Paul Gow^{1

2}

No abstract available

Comment in

Letter: TIPSS and reversal of sarcopenia.
Kumar K, Dixit I. Kumar K, et al. Aliment Pharmacol Ther. 2021 Jan;53(1):210. doi: 10.1111/apt.16129. Aliment Pharmacol Ther. 2021. PMID: 33333603 No abstract available.

Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective CT-based surveillance.
Artru F, Miquet X, Azahaf M, Labreuche J, Ntandja Wandji LC, Sergent G, Nobécourt A, Toumelin P, Lassailly G, Dharancy S, Ernst O, Mathurin P, Louvet A. Artru F, et al. Aliment Pharmacol Ther. 2020 Nov;52(9):1516-1526. doi: 10.1111/apt.16080. Epub 2020 Sep 15. Aliment Pharmacol Ther. 2020. PMID: 32931618
Letter: TIPSS and reversal of sarcopenia.
Kumar K, Dixit I. Kumar K, et al. Aliment Pharmacol Ther. 2021 Jan;53(1):210. doi: 10.1111/apt.16129. Aliment Pharmacol Ther. 2021. PMID: 33333603 No abstract available.
TIPSS and reversal of sarcopenia, and TIPSS is a promising therapy for sarcopenia in cirrhosis-Authors' reply.
Artru F, Labreuche J, Louvet A. Artru F, et al. Aliment Pharmacol Ther. 2021 Jan;53(1):211-212. doi: 10.1111/apt.16152. Aliment Pharmacol Ther. 2021. PMID: 33333608 No abstract available.

1. Artru F, Miquet X, Azahaf M, et al. Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective CT-based surveillance. Aliment Pharmacol Ther. 2020;52:1516-1526.
1. Tripathi D, Stanley AJ, Hayes PC, et al. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut. 2020;69:1173.
1. Davuluri G, Krokowski D, Guan B-J, et al. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis. J Hepatol. 2016;65:929-937.
1. Nardelli S, Lattanzi B, Gioia S, et al. Sarcopenia represents a risk factor for the development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Digest Liver Dis. 2017;49(Suppl. 2):e115-e116.
1. Sinclair M, Grossmann M, Hoermann R, Angus PW, Gow PJ. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: a randomised controlled trial. J Hepatol. 2016;65:906-913.